Log In
Print
BCIQ
Print
Print this Print this
 

mavoglurant (AFQ056)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionOral metabotropic glutamate receptor subtype 5 (mGluR5; GRM5) antagonist
Molecular Target Metabotropic glutamate receptor subtype 5 (mGluR5) (GRM5)
Mechanism of ActionMetabotropic glutamate receptor subtype 5 (mGluR5) antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II/III
Standard IndicationFragile X syndrome
Indication DetailsTreat Fragile X syndrome
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today